- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05848284
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US) (VISTA-US)
April 27, 2023 updated by: VDyne, Inc.
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pree Bassi
- Phone Number: 6124386888
- Email: pbassi@vdyne.com
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Rochester
-
Contact:
- Adam Logeman
- Phone Number: 507-422-2263
- Email: Logeman.Adam@mayo.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
- NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
- Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
- index procedure, including a diuretic.
- Heart Team determines patient is a recommended candidate for the VDyne System.
- Age >18 years at time of index procedure.
- Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for
- treatment with the VDyne System.
Exclusion Criteria:
- Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs or Clinical Screening Committee (CSC)
- Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
- Hypersensitivity to nickel or titanium
- Left Ventricular Ejection Fraction (LVEF) <30%.
- Severe RV dysfunction.
- Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
- Sepsis including active infective endocarditis (IE) (within last 6 months).
- Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
- Severe tricuspid annular or leaflets calcification.
- Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg.
- Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
- Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound).
- Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
- Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
- Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
- Significant valvular heart disease requiring intervention other than the tricuspid valve.
- Known significant intracardiac shunt (e.g. septal defect)
- Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
- Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
- Acute myocardial infarction (AMI) within 30 days.
- Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis.
- End-stage liver disease (MELD > 11 / CHILD class C).
- Bleeding requiring transfusion within prior 30 days.
- Coagulopathy or other clotting disorder that cannot be medically managed.
- Chronic immunosuppression or other condition that could impair healing response.
- Any of the following: leukopenia, chronic anemia (Hgb < 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
- Unwilling to receive blood products.
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
- Life expectancy less than 12 months due to non-cardiac comorbidities.
- Treatment is not expected to provide benefit (futile).
- Current IV Drug user (must be free drug abuse for > 1 year).
- Pregnant, lactating or planning pregnancy within next 12 months.
- Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
- Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
- Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
- Patient unable or unwilling to comply with study required testing and follow-up visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VDyne System Treatment Arm
Device
|
The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System.
The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB.
The valve is repositionable and fully retrievable intraoperatively.
Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Time Frame: Implant to 30 days post-procedure
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
|
Implant to 30 days post-procedure
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Time Frame: Baseline to 1 month after implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
|
Baseline to 1 month after implant
|
Changes in symptom status (NYHA class)
Time Frame: Baseline to 1 month after implant
|
Changes in symptom status (NYHA class)
|
Baseline to 1 month after implant
|
Changes in functional capacity (6-minute walk test)
Time Frame: Baseline to 1 month after implant
|
Changes in functional capacity (6-minute walk test)
|
Baseline to 1 month after implant
|
Changes in in quality of life (KCCQ score)
Time Frame: Baseline to 1 month after implant
|
Changes in in quality of life (KCCQ score).
A higher score indicates worsening quality of life outcomes
|
Baseline to 1 month after implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).
Time Frame: 30 days post-procedure to 1 year
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).
|
30 days post-procedure to 1 year
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Time Frame: 1 month after implant to 1 year post-implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
|
1 month after implant to 1 year post-implant
|
Changes in right ventricle as measured by core lab
Time Frame: 1 month after implant to 1 year post-implant
|
Changes in the right ventricle as measured by core lab
|
1 month after implant to 1 year post-implant
|
Rate of heart failure hospitalization
Time Frame: 1 month after implant to 1 year post-implant
|
Rate of heart failure hospitalization
|
1 month after implant to 1 year post-implant
|
Changes in symptom status (NYHA class)
Time Frame: 1 month after implant to 1 year post-implant
|
Changes in symptom status (NYHA class)
|
1 month after implant to 1 year post-implant
|
Changes in functional capacity (6-minute walk test)
Time Frame: 1 month after implant to 1 year post-implant
|
Changes in functional capacity (6-minute walk test)
|
1 month after implant to 1 year post-implant
|
Changes in in quality of life (KCCQ score).
Time Frame: 1 month after implant to 1 year post-implant
|
Changes in in quality of life (KCCQ score).
A higher score indicates worsening outcomes
|
1 month after implant to 1 year post-implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 30, 2023
Primary Completion (Anticipated)
November 30, 2025
Study Completion (Anticipated)
November 30, 2030
Study Registration Dates
First Submitted
March 29, 2023
First Submitted That Met QC Criteria
April 27, 2023
First Posted (Actual)
May 8, 2023
Study Record Updates
Last Update Posted (Actual)
May 8, 2023
Last Update Submitted That Met QC Criteria
April 27, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TPR0037-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tricuspid Regurgitation
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsActive, not recruitingTricuspid Regurgitation | Mild Tricuspid Regurgitation | Moderate Tricuspid RegurgitationUnited States, Canada, Germany
-
IRCCS Policlinico S. DonatoRecruitingTricuspid Regurgitation CongenitalItaly
-
Heart Center Leipzig - University HospitalRecruitingFunctional Tricuspid RegurgitationGermany
-
University of ZurichRecruitingSevere Tricuspid RegurgitationSwitzerland
-
P+F Products + Features GmbHCompletedSevere Tricuspid RegurgitationLithuania
-
Innoventric LTDNot yet recruitingTricuspid Regurgitation | Tricuspid Regurgitation Functional
-
Charite University, Berlin, GermanyRecruitingFunctional Tricuspid RegurgitationGermany, Israel
-
Michele De BonisCompleted
-
P+F Products + Features GmbHCompletedSevere Tricuspid RegurgitationSpain, Austria
-
TriFlo Cardiovascular, Inc.Not yet recruitingSymptomatic Severe Tricuspid RegurgitationItaly
Clinical Trials on VDyne Transcatheter Tricuspid Valve Replacement System
-
VDyne, Inc.RecruitingTricuspid Regurgitation | Tricuspid Valve Disease | Tricuspid Valvular DisordersAustralia, Czechia, Austria
-
Edwards LifesciencesActive, not recruitingCardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve RegurgitationUnited States, Canada, France, Switzerland
-
Montefiore Medical CenterThe Cleveland Clinic; University of Toronto; University Hospital, BordeauxEnrolling by invitationTricuspid RegurgitationUnited States, Canada, France
-
Edwards LifesciencesRecruitingCardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve RegurgitationJapan
-
Edwards LifesciencesRecruitingCardiovascular Diseases | Heart Failure | Heart Valve Diseases | Tricuspid Valve Regurgitation | Tricuspid Valve Insufficiency | Tricuspid Valve DiseaseUnited States, Germany
-
Edwards LifesciencesActive, not recruitingTricuspid RegurgitationUnited States
-
Changhai HospitalXijing Hospital; West China Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingTricuspid Valve InsufficiencyChina
-
Xijing HospitalNot yet recruitingTricuspid Regurgitation
-
Caisson Interventional LLCActive, not recruitingMitral Regurgitation | Valve Disease, Heart | Valve Heart Disease | Mitral Valve Disease | Mitral Valve Failure | Mitral DiseaseUnited States